← All drugs
Drug · FAERS side-effect profile with label screen

Lisinopril side effects: what 304,208 FDA adverse event reports show

Lisinopril · 1,171 reaction terms · 1,217,898 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Angiotensin converting enzyme (ace) inhibitor

FDA label, Indications wording

Who reports

304,208 reports · 61% serious · 25,263 with death outcome · 52% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial.

FDA label, Indications and Usage

What it is

Lisinopril is a dipeptide. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor.

PubChem CID 5362119 (ChEBI)

Boxed warning

FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue lisinopril as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 2Labeled adverse reaction 1Labeled (related wording) 1Likely indication confounding 1Lab value / disease marker 7Not in label — unassessed 28
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,131 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Intestinal angioedema26586.6
72.2–103.9ROR 86.7 · calibrated p 4e-7 ✓
38.2 EB05 34.5 · IC025 +5.0
3/3 methods agree
Labeled — boxed warning
exact term
serious n=264 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Lupus vulgaris52954.9
48.9–61.5ROR 55.0 · calibrated p 8e-6 ✓
30.6 EB05 28.5 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=529 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Anti-cyclic citrullinated peptide antibody26244.2
37.8–51.7ROR 44.3 · calibrated p 3e-5 ✓
27.0 EB05 24.4 · IC025 +4.5
3/3 methods agree
Lab value / disease markerserious n=262 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Chronic kidney disease-mineral and bone disorder38638.3
33.8–43.4ROR 38.3 · calibrated p 7e-5 ✓
24.7 EB05 22.7 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=386not reported in cached trials
Deep vein thrombosis postoperative66735.2
32.1–38.7ROR 35.3 · calibrated p 1e-4 ✓
23.4 EB05 22.0 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=667 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Neurologic neglect syndrome17932.1
26.8–38.3ROR 32.1 · calibrated p 2e-4 ✓
22.0 EB05 19.4 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=179 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Adjustment disorder with depressed mood63931.7
28.8–34.8ROR 31.8 · calibrated p 2e-4 ✓
21.8 EB05 20.4 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=635 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
C-reactive protein27629.8
25.9–34.4ROR 29.9 · calibrated p 3e-4 ✓
20.9 EB05 18.9 · IC025 +4.1
3/3 methods agree
Lab value / disease markerserious n=276 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Swollen joint count increased93929.4
27.2–31.7ROR 29.5 · calibrated p 3e-4 ✓
20.7 EB05 19.6 · IC025 +4.3
3/3 methods agree
Lab value / disease markerserious n=939 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Nephrogenic anaemia1,33427.2
25.6–29.0ROR 27.4 · calibrated p 4e-4 ✓
19.7 EB05 18.8 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=1,334not reported in cached trials
Dislocation of vertebra62226.5
24.1–29.0ROR 26.5 · calibrated p 5e-4 ✓
19.3 EB05 18.0 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=621 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
X-ray abnormal48925.7
23.2–28.6ROR 25.8 · calibrated p 6e-4 ✓
18.9 EB05 17.5 · IC025 +4.1
3/3 methods agree
Lab value / disease markerserious n=489 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Hyperparathyroidism secondary68225.1
23.0–27.5ROR 25.2 · calibrated p 7e-4 ✓
18.5 EB05 17.4 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=681not reported in cached trials
Rheumatic fever1,15024.4
22.8–26.1ROR 24.5 · calibrated p 8e-4 ✓
18.1 EB05 17.3 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=1,149 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Retinitis41022.2
19.8–24.8ROR 22.2 · calibrated p 0.001 ✓
16.9 EB05 15.6 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=409 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Rebound acid hypersecretion72921.3
19.6–23.1ROR 21.3 · calibrated p 0.001 ✓
16.4 EB05 15.4 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=729not reported in cached trials
Carotid artery thrombosis19820.6
17.5–24.1ROR 20.6 · calibrated p 0.002 ✓
15.9 EB05 14.2 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=198 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Rheumatoid factor positive1,23518.6
17.4–19.8ROR 18.6 · calibrated p 0.003 ✓
14.7 EB05 14.1 · IC025 +3.8
3/3 methods agree
Lab value / disease markerserious n=1,235 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Facet joint syndrome63417.1
15.7–18.7ROR 17.2 · calibrated p 0.004 ✓
13.8 EB05 13.0 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=632 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Anti-cyclic citrullinated peptide antibody positive1,41116.9
15.9–17.9ROR 16.9 · calibrated p 0.004 ✓
13.7 EB05 13.1 · IC025 +3.7
3/3 methods agree
Lab value / disease markerserious PRR 13.0 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Duodenal ulcer perforation1,42816.4
15.5–17.4ROR 16.5 · calibrated p 0.005 ✓
13.4 EB05 12.8 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious PRR 12.6 · ♀ 100% (drug 52%) · 95% cliniciannot reported in cached trials
Peripheral venous disease72015.0
13.8–16.2ROR 15.0 · calibrated p 0.007 ✓
12.4 EB05 11.7 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=712 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Brash syndrome21112.5
10.8–14.5ROR 12.5 · calibrated p 0.015 ✓
10.6 EB05 9.5 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=211 · ♀ 0% (drug 52%) · 100% cliniciannot reported in cached trials
End stage renal disease2,83112.4
11.9–12.9ROR 12.5 · calibrated p 0.015 ✓
10.6 EB05 10.3 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious PRR 10.0not reported in cached trials
Adjustment disorder20012.3
10.6–14.3ROR 12.3 · calibrated p 0.016 ✓
10.5 EB05 9.3 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=195 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Angioneurotic oedema41312.3
11.1–13.6ROR 12.3 · calibrated p 0.016 ✓
10.5 EB05 9.7 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=386 · ♀ 28% (drug 52%) · 100% cliniciannot reported in cached trials
Angioedema (deep swelling of face/throat)6,69312.2
11.9–12.5ROR 12.4 · calibrated p 0.015 ✓
10.4 EB05 10.2 · IC025 +3.3
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 13.2 · serious PRR 9.2 · ♀ 27% (drug 52%) · 94% cliniciannot reported in cached trials
Porphyria acute20712.0
10.3–13.9ROR 12.0 · calibrated p 0.017 ✓
10.2 EB05 9.1 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=206 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Helicobacter infection1,45611.3
10.7–12.0ROR 11.4 · calibrated p 0.020 ✓
9.8 EB05 9.4 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious PRR 9.8 · ♀ 100% (drug 52%) · 94% cliniciannot reported in cached trials
Muscle injury1,09310.4
9.8–11.1ROR 10.5 · calibrated p 0.027 ✓
9.2 EB05 8.7 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious PRR 9.3 · ♀ 100% (drug 52%) · 92% cliniciannot reported in cached trials
Pemphigus1,62910.3
9.7–10.8ROR 10.3 · calibrated p 0.029 ✓
9.0 EB05 8.7 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious PRR 8.5 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Sleep disorder due to general medical condition, insomnia type8009.6
9.0–10.4ROR 9.7 · calibrated p 0.036 ✓
8.5 EB05 8.0 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=772 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
C-reactive protein abnormal7809.4
8.7–10.2ROR 9.4 · calibrated p 0.039 ✓
8.4 EB05 7.9 · IC025 +2.9
3/3 methods agree
Lab value / disease markerserious n=777 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Chronic kidney disease9,1259.2
9.0–9.4ROR 9.4 · calibrated p 0.039 ✓
8.2 EB05 8.1 · IC025 +3.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 7.5 · serious PRR 7.9not reported in cached trials
Bone erosion4159.0
8.1–10.0ROR 9.0 · calibrated p 0.046 ✓
8.0 EB05 7.4 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=414 · ♀ 100% (drug 52%) · 100% cliniciannot reported in cached trials
Folliculitis1,1938.9
8.4–9.4ROR 8.9 · calibrated p 0.048 ✓
7.9 EB05 7.6 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious PRR 8.6 · ♀ 100% (drug 52%) · 92% cliniciannot reported in cached trials
Hand deformity1,4648.6
8.1–9.0ROR 8.6 · calibrated p 0.053
7.7 EB05 7.4 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious PRR 7.8 · ♀ 100% (drug 52%) · 94% cliniciannot reported in cached trials
Essential hypertension2898.5
7.6–9.7ROR 8.5 · calibrated p 0.055
7.6 EB05 6.9 · IC025 +2.7
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=252not reported in cached trials
Hypercholesterolaemia1,0318.2
7.7–8.8ROR 8.2 · calibrated p 0.061
7.4 EB05 7.0 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious PRR 7.3 · ♀ 87% (drug 52%)not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Anaphylaxis / angioedema7,7244.54.4–4.6signal
Kidney injury20,4383.23.1–3.2signal
Myocardial infarction7,3722.52.5–2.6signal
Gi bleeding6,3422.42.4–2.5signal
Heart failure6,1642.42.4–2.5signal
Pancreatitis2,7372.42.3–2.5signal
Hyperglycaemia / diabetes11,5242.32.3–2.4signal
Hyponatraemia2,5112.22.1–2.3signal
Hypoglycaemia2,7172.01.9–2.1raised
Arrhythmia / qt5,1381.91.8–1.9raised
Fall / fracture9,6861.81.7–1.8raised
Depression7,0151.71.7–1.8raised
Stroke6,1131.71.7–1.8raised
Anaemia6,7381.61.5–1.6raised
Rhabdomyolysis / myopathy1,7891.51.5–1.6raised
Serious infection16,2751.51.4–1.5raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Lisinopril as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Fatigue (tiredness)19,9141.8
1.8–1.8ROR 1.8 · calibrated p 0.855
1.8 EB05 1.7 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.8not reported in cached trials
Nausea18,4981.6
1.6–1.7ROR 1.7 · calibrated p 0.751
1.6 EB05 1.6 · IC025 +0.7Labeled — boxed warning
exact term
age-adj. PRR 1.5 · serious PRR 1.7NCT02603809: 1/81 (1.2%) on Lisinopril
Drug ineffective (drug did not work)17,6220.9
0.9–0.9ROR 0.9 · calibrated p 0.253
0.9 EB05 0.9 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 1.1 · serious PRR 1.0not reported in cached trials
Diarrhoea (diarrhea)17,3121.9
1.9–1.9ROR 1.9 · calibrated p 0.906
1.9 EB05 1.8 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.8NCT02603809: 1/81 (1.2%) on Lisinopril; 1/82 (1.2%) control
Dyspnoea (shortness of breath)13,9841.7
1.7–1.8ROR 1.8 · calibrated p 0.804
1.7 EB05 1.7 · IC025 +0.7Not in label — unassessedage-adj. PRR 1.5 · serious PRR 1.7NCT02603809: 1/81 (1.2%) on Lisinopril
Pain13,6381.5
1.5–1.6ROR 1.6 · calibrated p 0.684
1.5 EB05 1.5 · IC025 +0.6Labeled — boxed warning
exact term
age-adj. PRR 1.7 · serious PRR 1.6NCT02603809: 1/82 (1.2%) control
Dizziness13,5281.9
1.9–1.9ROR 1.9 · calibrated p 0.910
1.9 EB05 1.8 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.9NCT02603809: 1/81 (1.2%) on Lisinopril; 1/82 (1.2%) control
Headache13,0161.4
1.4–1.5ROR 1.5 · calibrated p 0.616
1.4 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.6NCT02603809: 4/81 (4.9%) on Lisinopril; 1/82 (1.2%) control
Off label use (used outside approved label)11,0490.9
0.9–0.9ROR 0.9 · calibrated p 0.225
0.9 EB05 0.9 · IC025 -0.2
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.8 · serious PRR 0.9not reported in cached trials
Vomiting11,0461.6
1.6–1.7ROR 1.7 · calibrated p 0.746
1.6 EB05 1.6 · IC025 +0.7Labeled — boxed warning
exact term
age-adj. PRR 1.6 · serious PRR 1.7NCT02603809: 1/82 (1.2%) control
Asthenia (weakness)10,9502.0
2.0–2.1ROR 2.1 · calibrated p 0.985
2.0 EB05 2.0 · IC025 +1.0Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 2.0NCT02603809: 1/82 (1.2%) on Lisinopril
Arthralgia (joint pain)9,6491.6
1.6–1.7ROR 1.6 · calibrated p 0.731
1.6 EB05 1.6 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.8NCT02603809: 1/82 (1.2%) on Lisinopril; 2/82 (2.4%) control
Acute kidney injury (sudden kidney damage)9,5474.5
4.5–4.6ROR 4.7 · calibrated p 0.275
4.3 EB05 4.2 · IC025 +2.1
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 2.8 · serious PRR 4.1not reported in cached trials
Chronic kidney disease9,1259.2
9.0–9.4ROR 9.4 · calibrated p 0.039 ✓
8.2 EB05 8.1 · IC025 +3.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 7.5 · serious PRR 7.9not reported in cached trials
Fall9,1161.9
1.9–2.0ROR 1.9 · calibrated p 0.913
1.9 EB05 1.9 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.5 · serious PRR 1.8NCT02603809: 1/81 (1.2%) on Lisinopril (serious AE)

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Lisinopril (ACE inhibitors) ↔ Angioedema.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Lisinopril?

In FDA FAERS, the most frequently co-reported reaction terms for Lisinopril are fatigue, nausea, diarrhoea, dyspnoea, pain, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Lisinopril have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue lisinopril as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Do FAERS signals prove that Lisinopril causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.